Literature DB >> 19548636

Rapid and efficient hydrophilicity tuning of p53/mdm2 antagonists.

Stuti Srivastava1, Barbara Beck, Wei Wang, Anna Czarna, Tad A Holak, Alexander Dömling.   

Abstract

The protein-protein interaction of p53 and mdm2 is an important anticancer target. The interface, however, is very hydrophobic and naturally results in very hydrophobic antagonists. We used the Orru three component reaction (O-3CR) along with a rapid and efficient, recently discovered amidation reaction to dramatically improve the water solubility of our recently discovered low molecular weight p53/mdm2 antagonists. Arrays of amides were synthesized with improved hydrophilicity and retainment and/or improvement of p53/mdm2 inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19548636      PMCID: PMC2891308          DOI: 10.1021/cc9000218

Source DB:  PubMed          Journal:  J Comb Chem        ISSN: 1520-4766


  13 in total

1.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.

Authors:  Susan L McGovern; Emilia Caselli; Nikolaus Grigorieff; Brian K Shoichet
Journal:  J Med Chem       Date:  2002-04-11       Impact factor: 7.446

2.  Absorption classification of oral drugs based on molecular surface properties.

Authors:  Christel A S Bergström; Melissa Strafford; Lucia Lazorova; Alex Avdeef; Kristina Luthman; Per Artursson
Journal:  J Med Chem       Date:  2003-02-13       Impact factor: 7.446

3.  Novel multicomponent reaction for the combinatorial synthesis of 2-imidazolines.

Authors:  Robin S Bon; Chongen Hong; Marinus J Bouma; Rob F Schmitz; Frans J J de Kanter; Martin Lutz; Anthony L Spek; Romano V A Orru
Journal:  Org Lett       Date:  2003-10-02       Impact factor: 6.005

Review 4.  Solubility: it's not just for physical chemists.

Authors:  Shobha N Bhattachar; Laura A Deschenes; James A Wesley
Journal:  Drug Discov Today       Date:  2006-09-26       Impact factor: 7.851

Review 5.  Small molecular weight protein-protein interaction antagonists: an insurmountable challenge?

Authors:  Alexander Dömling
Journal:  Curr Opin Chem Biol       Date:  2008-05-21       Impact factor: 8.822

6.  Multicomponent synthesis of 2-imidazolines.

Authors:  Robin S Bon; Bart van Vliet; Nanda E Sprenkels; Rob F Schmitz; Frans J J de Kanter; Christian V Stevens; Marcel Swart; F Matthias Bickelhaupt; Marinus B Groen; Romano V A Orru
Journal:  J Org Chem       Date:  2005-04-29       Impact factor: 4.354

Review 7.  MDM2 inhibitors for cancer therapy.

Authors:  Lyubomir T Vassilev
Journal:  Trends Mol Med       Date:  2006-11-28       Impact factor: 11.951

8.  Parallel synthesis of arrays of amino-acid-derived isocyanoamides useful as starting materials in IMCR.

Authors:  Alexander Dömling; Barbara Beck; Thilo Fuchs; Ahmad Yazbak
Journal:  J Comb Chem       Date:  2006 Nov-Dec

9.  Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence.

Authors:  Kensuke Kumamoto; Elisa A Spillare; Kaori Fujita; Izumi Horikawa; Taro Yamashita; Ettore Appella; Makoto Nagashima; Seiichi Takenoshita; Jun Yokota; Curtis C Harris
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

10.  A resource-efficient and highly flexible procedure for a three-component synthesis of 2-imidazolines.

Authors:  Niels Elders; Rob F Schmitz; Frans J J de Kanter; Eelco Ruijter; Marinus B Groen; Romano V A Orru
Journal:  J Org Chem       Date:  2007-07-12       Impact factor: 4.354

View more
  16 in total

Review 1.  Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2009.

Authors:  Roland E Dolle; Bertrand Le Bourdonnec; Karin Worm; Guillermo A Morales; Craig J Thomas; Wei Zhang
Journal:  J Comb Chem       Date:  2010-10-05

Review 2.  Chemistry and biology of multicomponent reactions.

Authors:  Alexander Dömling; Wei Wang; Kan Wang
Journal:  Chem Rev       Date:  2012-03-22       Impact factor: 60.622

3.  Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists.

Authors:  Yijun Huang; Siglinde Wolf; David Koes; Grzegorz M Popowicz; Carlos J Camacho; Tad A Holak; Alexander Dömling
Journal:  ChemMedChem       Date:  2011-09-27       Impact factor: 3.466

4.  Two strategies for the development of mitochondrion-targeted small molecule radiation damage mitigators.

Authors:  Jean-Claude M Rwigema; Barbara Beck; Wei Wang; Alexander Doemling; Michael W Epperly; Donna Shields; Julie P Goff; Darcy Franicola; Tracy Dixon; Marie-Céline Frantz; Peter Wipf; Yulia Tyurina; Valerian E Kagan; Hong Wang; Joel S Greenberger
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-13       Impact factor: 7.038

Review 5.  The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious.

Authors:  Grzegorz M Popowicz; Alexander Dömling; Tad A Holak
Journal:  Angew Chem Int Ed Engl       Date:  2011-02-21       Impact factor: 15.336

6.  Benzimidazole-2-one: a novel anchoring principle for antagonizing p53-Mdm2.

Authors:  Wei Wang; Haiping Cao; Siglinde Wolf; Miguel S Camacho-Horvitz; Tad A Holak; Alexander Dömling
Journal:  Bioorg Med Chem       Date:  2012-06-20       Impact factor: 3.641

7.  1,4-Thienodiazepine-2,5-diones via MCR (I): synthesis, virtual space and p53-Mdm2 activity.

Authors:  Yijun Huang; Siglinde Wolf; Michal Bista; Lidio Meireles; Carlos Camacho; Tad A Holak; Alexander Dömling
Journal:  Chem Biol Drug Des       Date:  2010-05-18       Impact factor: 2.817

Review 8.  P53 mdm2 inhibitors.

Authors:  Kareem Khoury; Alex Dömling
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

9.  A Van Leusen deprotection-cyclization strategy as a fast entry into two imidazoquinoxaline families.

Authors:  Fabio De Moliner; Christopher Hulme
Journal:  Tetrahedron Lett       Date:  2012-08-24       Impact factor: 2.415

10.  2,30-Bis(10H-indole) heterocycles: New p53/MDM2/MDMX antagonists.

Authors:  Constantinos G Neochoritis; Kan Wang; Natalia Estrada-Ortiz; Eberhardt Herdtweck; Katarzyna Kubica; Aleksandra Twarda; Krzysztof M Zak; Tad A Holak; Alexander Dömling
Journal:  Bioorg Med Chem Lett       Date:  2015-12-15       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.